Charles Schwab Investment Management Inc. purchased a new position in Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 73,146 shares of the company's stock, valued at approximately $1,498,000. Charles Schwab Investment Management Inc. owned 0.20% of Rapport Therapeutics at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Values First Advisors Inc. acquired a new position in shares of Rapport Therapeutics during the 3rd quarter worth $31,000. SG Americas Securities LLC purchased a new position in Rapport Therapeutics during the 3rd quarter valued at about $101,000. Sandia Investment Management LP purchased a new position in Rapport Therapeutics during the 2nd quarter valued at about $116,000. Davidson Kempner Capital Management LP acquired a new position in Rapport Therapeutics during the second quarter worth about $229,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at about $380,000.
Rapport Therapeutics Stock Performance
Rapport Therapeutics stock traded up $0.51 during mid-day trading on Tuesday, hitting $19.07. 110,000 shares of the company were exchanged, compared to its average volume of 153,429. Rapport Therapeutics has a 12-month low of $16.55 and a 12-month high of $29.74. The firm has a 50 day moving average price of $23.12.
About Rapport Therapeutics
(
Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
